{"id":"evolocumab-pre-filled-syringe","safety":{"commonSideEffects":[{"rate":"2-3","effect":"Injection site reactions"},{"rate":"5-8","effect":"Nasopharyngitis"},{"rate":"3-5","effect":"Upper respiratory tract infection"},{"rate":"2-3","effect":"Influenza"},{"rate":"2-3","effect":"Back pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PCSK9 is a protein that degrades LDL receptors on liver cells, reducing the liver's ability to remove LDL cholesterol from blood. By binding to and inhibiting PCSK9, evolocumab prevents this degradation, allowing more LDL receptors to remain on hepatocyte surfaces. This results in enhanced uptake and clearance of LDL cholesterol, significantly lowering blood LDL levels.","oneSentence":"Evolocumab is a monoclonal antibody that inhibits PCSK9, allowing increased clearance of LDL cholesterol from the bloodstream.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:11:56.133Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia (primary and secondary prevention of cardiovascular events)"},{"name":"Familial hypercholesterolemia"}]},"trialDetails":[{"nctId":"NCT03869073","phase":"PHASE2","title":"Evolocumab for PCSK9 Lowering in Early Acute Sepsis (The PLEASe Study)","status":"UNKNOWN","sponsor":"University of British Columbia","startDate":"2019-02-11","conditions":"Sepsis","enrollment":36},{"nctId":"NCT01849497","phase":"PHASE3","title":"Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-04-18","conditions":"Primary Hypercholesterolemia, Mixed Dyslipidemia","enrollment":149}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AMG 145","Repatha"],"phase":"phase_3","status":"active","brandName":"Evolocumab Pre-filled Syringe","genericName":"Evolocumab Pre-filled Syringe","companyName":"Amgen","companyId":"amgen","modality":"Biologic","firstApprovalDate":"","aiSummary":"Evolocumab is a monoclonal antibody that inhibits PCSK9, allowing increased clearance of LDL cholesterol from the bloodstream. Used for Hypercholesterolemia (primary and secondary prevention of cardiovascular events), Familial hypercholesterolemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}